COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
13 août 2024 08h05 HE
|
COSCIENS Biopharma Inc.
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...